title: Role of hedgehog signaling in ovarian cancer.
abstract: OBJECTIVE
  In humans, several distinctive cancers result from mutations that aberrantly activate hedgehog (HH) signal transduction. Here, we investigate the role of HH signaling in ovarian cancer.
  
  
  METHODS
  We assessed the expression of different components of hedghehog pathway in primary tumor samples and cell lines. We used specific hedghehog pathway blocker to study the effect on clonal growth and proliferation of ovarian cancer cell both in vitro and in vivo.
  
  
  RESULTS
  We show that the up-regulation of several HH pathway components is a common feature of primary ovarian tumors and cell lines. However, expression of PATCHED1 (PTCH1), a direct transcriptional target of the HH pathway, is down-regulated in ovarian cancer in direct contrast to the expression observed in other adult solid tumors. Cyclopamine, a specific HH pathway inhibitor, inhibits the proliferation and clonal growth of ovarian tumor cells in vitro and arrests ovarian tumor growth in vivo. Expression of BMI-1, a polycomb gene, is down-regulated in ovarian cancer cells following cyclopamine treatment. Overexpression of PTCH1 phenocopied the effects of cyclopamine; it down-regulated BMI-1 and reduced clonal growth in ovarian cancer cell lines. Furthermore, knocking down BMI-1 using small interfering RNA also inhibited the clonal growth of all the ovarian cancer cell lines tested.
  
  
  CONCLUSIONS
  In brief, the constitutive low-level expression of PTCH1 contributes to proliferation and clonal growth of ovarian cancer cells by an aberrant HH signal. Because the HH pathway can be inhibited by specific inhibitors, these findings point toward possible new treatments to inhibit ovarian cancer growth.
authors.affiliation: Department of Biochemistry and Molecular Biology, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA. bhattacharya.resham@mayo.edu
authors.forename: Resham
authors.initials: R
authors.lastname: Bhattacharya
authors.forename: Junhye
authors.initials: J
authors.lastname: Kwon
authors.forename: Bushra
authors.initials: B
authors.lastname: Ali
authors.forename: Enfeng
authors.initials: E
authors.lastname: Wang
authors.forename: Sujata
authors.initials: S
authors.lastname: Patra
authors.forename: Viji
authors.initials: V
authors.lastname: Shridhar
authors.forename: Priyabrata
authors.initials: P
authors.lastname: Mukherjee
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D015153:Blotting, Western; D045744:Cell Line, Tumor; D005260:Female; D053823:Hedgehog Proteins / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*; D014162:Transfection; D014704:Veratrum Alkaloids / Q000494:pharmacology*; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D053823:Hedgehog Proteins; D014704:Veratrum Alkaloids; C000541:cyclopamine